title: Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine.
authors.forename: Milos
authors.initials: M
authors.lastname: Opravil
authors.forename: Doris
authors.initials: D
authors.lastname: Baumann
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Chave
authors.forename: Hansjakob
authors.initials: H
authors.lastname: Furrer
authors.forename: Alexandra
authors.initials: A
authors.lastname: Calmy
authors.forename: Enos
authors.initials: E
authors.lastname: Bernasconi
authors.forename: Monika
authors.initials: M
authors.lastname: Blasko
authors.forename: Pietro
authors.initials: P
authors.lastname: Vernazza
authors.forename: Bruno
authors.initials: B
authors.lastname: Ledergerber
authors.forename: Luc
authors.initials: L
authors.lastname: Perrin
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D015224:Dideoxynucleosides / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D013997:Time Factors; D017211:Treatment Failure; D015215:Zidovudine / Q000008:administration & dosage; D000099227:Abacavir
chemical_list: D015224:Dideoxynucleosides; D017320:HIV Protease Inhibitors; D019259:Lamivudine; D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine; D000099227:Abacavir